Research ArticleCancer therapy

High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors

See allHide authors and affiliations

Science Signaling  16 Jun 2020:
Vol. 13, Issue 636, eaay1451
DOI: 10.1126/scisignal.aay1451

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Speedy screen for tumor therapies

Although cell death screens using patient biopsies could be used to identify effective, personalized treatments, it takes several days to obtain results, meaning that the cells ultimately guiding treatment decisions may become molecularly different than those in the patient. Bhola et al. developed a high-throughput method (called HT-DBP) that identifies, within 24 hours, drugs that initiate cell death programs in tumor cells from freshly isolated patient biopsies. HT-DBP identified single agents and combinations that shrunk breast and colon tumors in mice but that would not have seemed as promising when screened after the usual multiday period of culture outgrowth. The findings may enable a fast and broadly applicable tumor screening technique to guide effective treatment decisions for patients.

View Full Text

Stay Connected to Science Signaling